Dermatology is an area of medicine dealing specifically with the skin. Skin diseases have a serious impact on people's quality of life. Dermatology therapeutics are used to treat increasing cases of pigmented skin, skin resurfacing, skin tightening, and age-related dermal/vascular lesions, among others. Dermatology treatments are non-invasive require less time, cost-effective, and offer better results as compared to surgeries.

Market Dynamics:

Rise in burden of dermatology diseases, growing geriatric population, rise in demand for safe and effective therapeutics, rise in awareness among people, increase in research and development, and frequent approvals and launches of novel therapeutics are major factors expected to drive growth of the global dermatological therapeutic market.

For instance, in July 2022, Almirall announced the launch of its 7^th call through AlmirallShare, its open innovation platform, for proposals to establish collaborations in dermatological research. The aim of this is to find new partnership opportunities for assets in preclinical or clinical development stages that can become new treatments for skin diseases.

Moreover, in February 2021, Bristol Myers Squibb announced positive results from two pivotal Phase 3 trials evaluating deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to severe plaque psoriasis.

Key features of the study:

• This report provides in-depth analysis of the global dermatological therapeutic market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global dermatological therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Leo Pharma, Pfizer Inc., Novartis AG, Johnson & Johnson, GlaxoSmithKline PLC, Galderma, Amgen Inc., Almirall, S.A., XBiotech USA Inc., AbbVie Inc, and Bausch Health Companies Inc., among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global dermatological therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatological therapeutic market.

Detailed Segmentation:

• Global Dermatological Therapeutic Market., By Application:
  • Alopecia
  • Herpes
  • Psoriasis
  • Rosacea
  • Atopic Dermatitis
  • Acne Vulgaris
  • Vitiligo
  • Hidradenitis
  • Other Applications
• Global Dermatological Therapeutic Market, By Drug Class:
  • Anti-infectives
  • Corticosteroids
  • Calcineurin Inhibitors
  • Retinoids
  • Other Drug Classes
• Global Dermatological Therapeutic Market, By Geography:
  • North America
  • Europe
  • Asia Pacific
  • Middle East 
  • Africa
  • Latin America
• Company Profiles:
  • Leo Pharma
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • GlaxoSmithKline PLC
  • Galderma, Amgen Inc.
  • Almirall, S.A.
  • XBiotech USA Inc.
  • AbbVie Inc.
  • Bausch Health Companies Inc.